We are honored to invite Dr. Mark Leick to introduce a novel approach that leverages CAR-T cells for the targeted delivery of anti-VEGF therapeutics. Join us to explore how these engineered CAR-T cells (CARVEGF) function as "Trojan horses" to unleash a dual-pronged attack: directly targeting tumor cells while simultaneously delivering localized VEGF blockade to disrupt tumor angiogenesis.
